A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation.A Blood and Marrow Transplant Clinical Tri

Publication Type:

Journal Article

Source:

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2014)

Keywords:

2014, April 2014, Clinical Research Division

Abstract:

Idiopathic Pneumonia Syndrome (IPS) is a diffuse, non-infectious lung injury that occurs acutely after allogeneic hematopoietic cell transplant (HCT). IPS related mortality has been historically high (>50%) despite treatment with systemic corticosteroids and supportive care measures. The role of TNF inhibition is examined in a randomized, double-blind, placebo controlled trial of corticosteroids with etanercept or placebo.